L & S Advisors’s Axsome Therapeutics AXSM Stock Holding History

L & S Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$330K	–	301
2021 Q3	$330K	Buy	+10,000	New	+$390K	0.04%	273

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

L & S Advisors's AXSM Position: Q4 2021 in Review

L & S Advisors sold out of Axsome Therapeutics (AXSM) in Q4 2021, closing a stake of 10,000 shares — an estimated $330K sold.

L & S Advisors first reported a position in AXSM in Q3 2021 and held it in 1 quarter. The position peaked at $330K in Q3 2021. 167 funds tracked by Wall St. Rank hold AXSM as of Q4 2021.

L & S Advisors reported no remaining Axsome Therapeutics position as of Q4 2021 after selling out during the quarter.
L & S Advisors sold 10,000 Axsome Therapeutics shares in Q4 2021, an estimated $330K.
L & S Advisors first reported a position in Axsome Therapeutics in Q3 2021 and held it in 1 quarter.
L & S Advisors's Axsome Therapeutics position peaked at $330K in Q3 2021.
167 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2021.

Based on L & S Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.